NO20074515L - Fremgangsmate til prognose for mentale sykdommer, f.eks. autisme og cerebral parese - Google Patents

Fremgangsmate til prognose for mentale sykdommer, f.eks. autisme og cerebral parese

Info

Publication number
NO20074515L
NO20074515L NO20074515A NO20074515A NO20074515L NO 20074515 L NO20074515 L NO 20074515L NO 20074515 A NO20074515 A NO 20074515A NO 20074515 A NO20074515 A NO 20074515A NO 20074515 L NO20074515 L NO 20074515L
Authority
NO
Norway
Prior art keywords
sample
cerebral palsy
autism
behavioral analysis
forecasting
Prior art date
Application number
NO20074515A
Other languages
English (en)
Inventor
Frank Hoover
Original Assignee
Tipogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tipogen As filed Critical Tipogen As
Publication of NO20074515L publication Critical patent/NO20074515L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for prognose for anvendt atferdsanalysebehandling for en mental sykdom, særlig autisme eller cerebral parese, i et menneske, hvor nevnte metode omfatter å analysere en prøve av kroppsvev eller fluid fra nevnte individ for nærvær eller fravær av en kjemisk markør som indikerer sannsynligheten for vellykkethet eller mislykkethet av anvendt atferdsanalysebehandling av nevnte mentalsykdom, og eventuelt, basert på nevnte analyse, å igangsette, fortsette eller avslutte anvendt atferdsanalysebehandling av nevnte individ. Prøven er fortrinnsvis en urinprøve og de foretrukne prognostiske markører er; glutenderivater, indolyl-3akryloylglysin (IAG), serotoninopptaksstimulator, p-kasomorfinamider, gliadinomorfin, P-kasomorfiner, deltorfiner, Demorfin, glutemorfin, gluten eksofiner, forbindelser med molekylvekt på 687 Dalton.
NO20074515A 2005-02-28 2007-09-06 Fremgangsmate til prognose for mentale sykdommer, f.eks. autisme og cerebral parese NO20074515L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504096.9A GB0504096D0 (en) 2005-02-28 2005-02-28 Method
PCT/GB2006/000699 WO2006090185A1 (en) 2005-02-28 2006-02-28 Method of prognosis of mental diseases, e. g. autism and cerebral palsy

Publications (1)

Publication Number Publication Date
NO20074515L true NO20074515L (no) 2007-09-06

Family

ID=34430346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074515A NO20074515L (no) 2005-02-28 2007-09-06 Fremgangsmate til prognose for mentale sykdommer, f.eks. autisme og cerebral parese

Country Status (12)

Country Link
US (1) US20090011452A1 (no)
EP (1) EP1853922A1 (no)
JP (1) JP2008532033A (no)
CN (1) CN101189522A (no)
AU (1) AU2006217658A1 (no)
CA (1) CA2598945A1 (no)
EA (1) EA200701602A1 (no)
GB (1) GB0504096D0 (no)
IL (1) IL185554A0 (no)
NO (1) NO20074515L (no)
WO (1) WO2006090185A1 (no)
ZA (1) ZA200707230B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9128168B2 (en) * 2007-12-14 2015-09-08 Cornell University Method of determing excretion of sodium and other analytes
US8703424B2 (en) 2010-03-22 2014-04-22 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
AU2011248464B2 (en) 2010-04-29 2016-08-11 Stemina Biomarker Discovery, Inc. Metabolic biomarkers of autism
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
WO2016069801A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders
CA2966360C (en) 2014-10-30 2023-09-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法
CN121534089A (zh) 2016-05-23 2026-02-17 加州理工学院 调节肠微生物群来治疗神经退行性病症
US10001103B1 (en) 2016-12-15 2018-06-19 Borgwarner, Inc. System with multiple starters and smart relay
WO2018213204A1 (en) 2017-05-15 2018-11-22 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
GB201802116D0 (en) 2018-02-09 2018-03-28 Univ Warwick Methods for diagnosing an autistic spectrum disorder
RU2698634C1 (ru) * 2019-03-18 2019-08-28 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ прогнозирования риска развития детского церебрального паралича у детей, родившихся в сроке сверхранних преждевременных родов, на первом году жизни
CN115616227B (zh) * 2022-11-18 2023-05-16 四川大学华西医院 吲哚-3-丙烯酰甘氨酸检测试剂的用途、诊断或辅助诊断慢性阻塞性肺病的试剂盒及系统
CN115711954B (zh) * 2022-11-18 2024-07-23 重庆医科大学 用于诊断儿童青少年抑郁症的尿液生物标志物组合及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
CA2273683A1 (en) * 1998-06-15 1999-12-15 Ortho-Clinical Diagnostics, Inc. Diagnostic markers for human disorders
US6534063B1 (en) * 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
AU2003244205A1 (en) * 2002-07-04 2004-01-23 Mitsubishi Pharma Corporation Method of examining and diagnosing integration dysfunction syndrome
FR2857452B1 (fr) * 2003-07-11 2005-09-30 Univ Rabelais Francois Test de depistage de l'autisme, methode de selection de patients repondant audit test et utilisation des medicaments activateurs de canaux bkca pour le traitement de ladite maladie
DE602004021186D1 (de) * 2003-08-22 2009-07-02 Integragen Sa Menschliches autismus-suszeptibilitätsgen und verwendungen davon

Also Published As

Publication number Publication date
ZA200707230B (en) 2008-11-26
US20090011452A1 (en) 2009-01-08
WO2006090185A1 (en) 2006-08-31
GB0504096D0 (en) 2005-04-06
CA2598945A1 (en) 2006-08-31
AU2006217658A1 (en) 2006-08-31
CN101189522A (zh) 2008-05-28
JP2008532033A (ja) 2008-08-14
IL185554A0 (en) 2008-01-06
EP1853922A1 (en) 2007-11-14
EA200701602A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
NO20074515L (no) Fremgangsmate til prognose for mentale sykdommer, f.eks. autisme og cerebral parese
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
Gregersen et al. Blood transfusion and overall quality of life after hip fracture in frail elderly patients—the transfusion requirements in frail elderly randomized controlled trial
NO20030251L (no) Fremgangsmåte for differensiering mellom biologiske tilstander basert på skjulte mönstre fra biologiske data
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
EP2306192A3 (en) Risk Markers For Cardiovascular Disease
WO2006073682A3 (en) Diagnostic test
WO2007086986A3 (en) Novel application of biosensors for diagnosis and treatment of disease
DE60204336D1 (de) Atemfunktionsanalyse mittels kapnographie
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
DK1342794T3 (da) Fremgangsmåde og anordning til at bestemme vævsspecificitet af fritflydende DNA i legemsvæsker
NO20080371L (no) Fremgangsmate for a forutsi responsen overfor en behandling
WO2008055491A3 (de) Diagnose und risikostratifizierung von diabetes mellitus mittels mr-proadm
WO2006081521A3 (en) Methods for diagnosis and intervention of hepatic disorders
WO2008027912A3 (en) Prediction of an agent's or agents' activity across different cells and tissue types
DK1515752T3 (da) ACE2-aktivering til behandling af hjerte-, lunge- og nyresygdomme og hypertension
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
WO2005098041A3 (en) Detection and treatment of fibrotic disorders
Rozgaj et al. Genotoxic effects of anaesthetics in operating theatre personnel evaluated by the comet assay and micronucleus test
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
WO2005015155A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
Guzmán et al. H2O2 concentration in exhaled breath condensate increases after phonotrauma: a promise of noninvasive monitoring?
AU2003250938A1 (en) Method for determination of thymidine kinase 1 activity and the use thereof
WO2005056839A3 (de) Primer und sonden zum nachweis genitaler hpv-genotypen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application